In animal and preliminary human studies, BPC 157 showed the ability to: Accelerate regeneration of muscles, tendons, and ligaments Support brain and nervous system function Influence the lining of the gut Reduce inflammation markers Support sleep quality Enhance mood and mental clarity Promote blood vessel formation in injured tissues Support bone density and connective tissue integrity All of this from something born in the stomach
Allow at least 1 inch (2.5 cm) between injection sites within the same session if administering multiple peptides
Dozens of studies show it protects rat stomach lining against NSAIDs, alcohol, and stress-induced ulcers
This step-by-step reference is designed to minimize administrative burden and optimize the billing process
Browse the menu, pick your blend, and let our team handle the rest
"As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease." The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine
